ATRIUMX Pharmacy Conference and the Truth about GLP-1 Drugs | TWIRx

The Next Gen Pharmacy Conference, ATRIUMX February 27 – March 1, 2025 The conference that puts you in control— you create the content. 

Thank you Independent Pharmacy Cooperative (IPC) for sponsoring this episode of TWIRx! 
Check out the iCare+ digital health platform: https://myicareplus.com/ 

2-Part Special: 

FIRST -- Special guests: Atrium24 founder, Dr. Nicolette Mathey PharmD, ATRIUMX organizers Kelley Babcock, and Jen Diehl, and Pharmacy Busienss Consultant and owner Donnie Jordan Vice President Pharmacy Strategy at Health Growth Pharmacy Solutions. 

SIGN UP HERE: https://atrium24.io/atriumx-conference-attendees/ 

NEXT -- on the second half of TWIRx, we talk with Dr. Julie Schulz, MD, MPH and Dr. Michael Dovidio, PharmD from Avalon Health talk about the challenges of 'quick fix' treatments and weight management plans with the inclusion of GLP-1s. From the article titled: "How to Maximize the Value of GLP-1 Drugs While Improving Health Equity" --Julie and Mike talk about the real world needs of people who want to lose weight, doing it the right way for long term benefit. 

Due to the continued high cost, only patients with greater financial resources or those with generous employer-sponsored drug benefits will be able to afford the medications for obesity. This can exacerbate health inequities, likely driving significantly higher costs for public and commercial health plans, intensified by the new financial strain from weight loss medications.

Rather than denying coverage for GLP-1s for obesity, health plans could modify eligibility policies to require data from a standardized set of laboratory tests and other biometrics to identify patients in most need of GLP-1s and verify medical necessity. This approach would reduce inappropriate prescribing while ensuring that patients who are most likely to benefit from the drugs have access to them.